| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/27/2000 | CA2333895A1 Snurportin i human m3g-cap specific nucleus import receptor protein with new domain structure, the production and use thereof |
| 01/27/2000 | CA2333467A1 Human presenilin-associated protein |
| 01/27/2000 | CA2303062A1 Human aspartic proteases |
| 01/26/2000 | EP0974664A2 Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme |
| 01/26/2000 | EP0974663A1 Lipoprotein associated phospholipase A2, inhibitors thereof and use of same in diagnosis and therapy |
| 01/26/2000 | EP0974660A1 Newcastle disease virus infectious clones, vaccines and diagnostic assays |
| 01/26/2000 | EP0974659A2 Viral nucleotide sequences |
| 01/26/2000 | EP0974653A2 Human gastric cancer antigen gene and protein |
| 01/26/2000 | EP0974651A1 Physiologically active protein originating in mammals |
| 01/26/2000 | EP0974357A1 Chemokines as adjuvants of immune response |
| 01/26/2000 | EP0973942A2 Screening method for proline-rich proteins |
| 01/26/2000 | EP0973934A1 Transgenically produced non-secreted proteins |
| 01/26/2000 | EP0973925A2 Matrix derived anti-hiv peptides and transdominant proteins |
| 01/26/2000 | EP0973924A1 Recombinant chimeric viruses and uses thereof |
| 01/26/2000 | EP0973916A1 Composition and method for inducing an immune response against tumour-related antigens |
| 01/26/2000 | EP0973911A1 MUTANT $i(msbB) or $i(htrB) GENES |
| 01/26/2000 | EP0973909A2 Process for extracting and purifying recombinant, non-lipidised osp-protein |
| 01/26/2000 | EP0973894A1 Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use |
| 01/26/2000 | EP0973891A1 Human chemokine receptor-like chemokine |
| 01/26/2000 | EP0973881A2 Mycobacterium recombinant vaccines |
| 01/26/2000 | EP0973879A2 Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products |
| 01/26/2000 | EP0973865A2 Attenuated, invasive vaccines against fish pathogens |
| 01/26/2000 | EP0973864A1 Novel microorganisms |
| 01/26/2000 | EP0973804A2 Anti-vegf antibodies |
| 01/26/2000 | EP0973803A1 Peptides useful for reducing symptoms of toxic shock syndrome |
| 01/26/2000 | EP0973802A1 Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses |
| 01/26/2000 | EP0973794A1 Netrin receptors |
| 01/26/2000 | EP0973550A1 Antagonistic anti-avb3 integrin antibodies |
| 01/26/2000 | EP0973549A2 Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
| 01/26/2000 | EP0973548A1 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| 01/26/2000 | EP0973547A1 Improving binding affinity of antigenic peptides for mhc molecules |
| 01/26/2000 | EP0973546A2 Stabilized human papillomavirus formulations |
| 01/26/2000 | EP0973545A1 Leishmania vaccine |
| 01/26/2000 | EP0973536A1 Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| 01/26/2000 | EP0973534A1 Pharmaceutical compositions having appetite suppressant activity |
| 01/26/2000 | EP0973394A1 NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO $i(HELICOBACTER PYLORI) AND VACCINE COMPOSITIONS THEREOF |
| 01/26/2000 | EP0973381A2 Animal model for evaluation of vaccines |
| 01/26/2000 | EP0743870B1 Preparation and application of artificial anti-idiotypic imprints |
| 01/26/2000 | EP0700305B1 Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them |
| 01/26/2000 | EP0587735B1 T cell receptor peptides as therapeutics for immune-related disease |
| 01/26/2000 | CN1242802A Notch protein and their ligands |
| 01/26/2000 | CN1242376A Human nervous specific expression gene |
| 01/26/2000 | CN1048731C Polynucleotide of drug binding protein as coded CSAID |
| 01/25/2000 | US6018019 Immunogenic synthetic peptides which are useful alone or in conjugates in vaccines against hemophilus influenza infection |
| 01/25/2000 | US6017897 Nucleic acid respiratory syncytial virus vaccines |
| 01/25/2000 | US6017763 G-beta-gamma regulated phosphatidylinositol-3' kinase |
| 01/25/2000 | US6017759 Chimeric infectious bursal disease virus cDNA clones, expression products and vaccines based thereon |
| 01/25/2000 | US6017757 A homogenous cell population of parasitic cells obtained by in-vitro culturing of differentiated intestinal cells of a nematode; therapy and prevention of parasitic infections in animals |
| 01/25/2000 | US6017729 Receptor activator of NF-κB |
| 01/25/2000 | US6017728 ribH |
| 01/25/2000 | US6017705 Nucleic acid molecules that codes for tumor rejection antigens; diagnosis and screening for possible presence of lymphoma, or head and neck squamous cell carcinoma, skin and mammary carcinomas |
| 01/25/2000 | US6017545 Mixed micellar delivery system and method of preparation |
| 01/25/2000 | US6017544 Isolating stress protein-peptide complex from tumor cells previously removed from a mammal and administering the isolated stress protein-peptide complex along with a cytokine to the mammal in order to stimulate an immune response |
| 01/25/2000 | US6017542 Nucleotide and amino acid sequences of canine herpesvirus GD and uses therefor |
| 01/25/2000 | US6017540 Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
| 01/25/2000 | US6017539 Multimeric hybrid genes encoding corresponding chimeric protein comprise gene sequence coding for antigenic region of protein from first pathogen linked to gene sequence coding for antigenic region of protein from second pathogen |
| 01/25/2000 | US6017537 Immunological adjuvants comprised of the n-formyl methionyl peptide fmlp used as an adjuvant to provide for an immune response to suboptimal doses of recombinant antigens |
| 01/25/2000 | US6017536 Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
| 01/25/2000 | US6017535 cDNA sequence of Dengue virus serotype 1 (Singapore strain) |
| 01/25/2000 | CA1340880C Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins |
| 01/25/2000 | CA1340879C Recombinant dna product and methods |
| 01/25/2000 | CA1340878C Production of human t-cell leukemia (lymphotropic) retrovirus (htlv-i) envelope protein fragments in bacteria and use in seroepidemiological survey of human lymphoid malignancies |
| 01/20/2000 | WO2000003036A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | WO2000003016A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | WO2000003015A2 Human transport protein homologs |
| 01/20/2000 | WO2000002925A1 Lupus anticoagulant antibody to f1 region of prothrombin |
| 01/20/2000 | WO2000002924A1 Papillomavirus cellular receptor |
| 01/20/2000 | WO2000002923A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002917A2 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | WO2000002913A1 Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
| 01/20/2000 | WO2000002911A2 INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON) |
| 01/20/2000 | WO2000002897A2 Delta cleavage products and methods based thereon |
| 01/20/2000 | WO2000002860A1 2-aminopyridine erivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | WO2000002591A1 Polynucleotide vaccine formulations |
| 01/20/2000 | WO2000002587A1 Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| 01/20/2000 | WO2000002584A2 Cancer treatment methods using antibodies to aminophospholipids |
| 01/20/2000 | WO2000002583A1 Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
| 01/20/2000 | WO2000002582A2 Treatment of celiac disease with interleukin-15 antagonists |
| 01/20/2000 | WO2000002581A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | WO2000002574A1 Powdery preparation for mucosal administration containing polymeric medicine |
| 01/20/2000 | WO2000002573A1 Natural composition and method for the treatment of sexual dysfunction |
| 01/20/2000 | WO2000002521A2 Symptomatic relief of allergic reactions |
| 01/20/2000 | WO2000002520A2 T-lymphocyte exchange |
| 01/20/2000 | WO1999059633A8 Therapeutics using a bispecific anti-hla class ii invariant chain x anti-pathogen antibody |
| 01/20/2000 | WO1999059627A3 Verotoxin b subunit for immunization |
| 01/20/2000 | WO1999056773A3 Composition comprising tumor cells and extracts and method of using thereof |
| 01/20/2000 | WO1999055347A3 Treatment of papilloma virus infection using a mycobacterium |
| 01/20/2000 | WO1999047674A3 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/20/2000 | WO1999040115A9 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT |
| 01/20/2000 | WO1998042376A9 Composition comprising immunoglobulin |
| 01/20/2000 | WO1998027107A8 Method of coupling polysaccharides to proteins |
| 01/20/2000 | CA2748996A1 Antigenic peptides derived from telomerase |
| 01/20/2000 | CA2337258A1 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them |
| 01/20/2000 | CA2337101A1 Papillomavirus cellular receptor |
| 01/20/2000 | CA2336992A1 Polynucleotide vaccine formulations |
| 01/20/2000 | CA2335382A1 Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe |
| 01/20/2000 | CA2335090A1 Immunological reagent specifically interacting with the extracellular domain of the human zeta chain |
| 01/20/2000 | CA2334078A1 Lupus anticoagulant antibody to f1 region of prothrombin |
| 01/20/2000 | CA2333928A1 Compounds and methods for modulating cadherin-mediated functions |
| 01/20/2000 | CA2333923A1 Treatment of celiac disease with interleukin-15 antagonists |